A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

For this study, they are looking for children and young adults between 6 months and 25 years old. People who might be able to join have either a specific type of brain tumour called low-grade glioma, or an advanced solid tumour. For both conditions, the tumour must have either returned or gotten worse after other treatments.

Crucially, the doctors need to find specific genetic changes within the tumour cells. This is a very important part of deciding if someone can join the study, as the medicine is designed to work best when these changes are present. Participants must also have had at least one previous treatment for their cancer that didn't fully work.

However, there are also reasons someone might not be able to join. For example, if their tumour has other known genetic changes that could interfere with the study, or if they have a condition called neurofibromatosis type 1 (NF-1). The medical team will carefully review each person's health to see if the study is a good fit.

If you consider joining this study, it would involve several stages. First, there's a 'screening period' where doctors will do tests, including looking for specific genetic changes in your tumour. If you qualify and decide to take part, you'll then move into the 'treatment period' where you will receive the study medicine, Tovorafenib. You'll have regular appointments for check-ups and to see how you're responding to the treatment. This will involve appointments at the hospital or clinic.

After the main treatment period, some participants may enter a 'long-term extension phase', meaning they might continue to receive the medicine if it's helping. Once treatment stops, there will be 'end of treatment' visits, followed by safety check-ups to monitor your well-being. Finally, there will be 'long-term follow-up assessments' to keep an eye on your health over a longer period. The total duration of your participation would depend on how you respond to the treatment and the study's specific plan, but it will involve ongoing check-ups for some time.